An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II
NCT05754450 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2
Last updated 2026-05-01
Summary
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
Conditions
- Leukocyte Adhesion Deficiency
Interventions
- DRUG
-
AVTX-803
L-fucose crystalline powder
Sponsors & Collaborators
-
AUG Therapeutics
lead INDUSTRY
Principal Investigators
-
David Deyle · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 6 Months
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-10
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
NCT04638829 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
NCT01433978 ·Status: TERMINATED ·Phase: PHASE3
-
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
NCT04993885 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
NCT07039422 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
NCT03812263 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Avatrombopag Combined With IST as First-line Treatment for SAA
NCT05720234 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers
NCT06630494 ·Status: COMPLETED ·Phase: PHASE1
-
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
NCT07252050 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
NCT00625443 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura
NCT00486421 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
NCT06282432 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)
NCT02223117 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
NCT01438840 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
NCT03837483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
NCT07278908 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
NCT00571467 ·Status: TERMINATED ·Phase: PHASE1
-
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
NCT04323748 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT04274452 ·Status: WITHDRAWN ·Phase: PHASE3
-
Thrombosomes® in Bleeding Thrombocytopenic Patients
NCT03394755 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
NCT04224688 ·Status: TERMINATED ·Phase: PHASE3
-
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
NCT03275740 ·Status: TERMINATED ·Phase: PHASE1
-
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
NCT05046327 ·Status: WITHDRAWN ·Phase: PHASE3
-
Extended Dosing With Eltrombopag for Severe Aplastic Anemia
NCT01891994 ·Status: COMPLETED ·Phase: PHASE2
-
The Holistic Study
NCT07051915 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3